FIGURE 1.

A, Intratumorally administration of mAbs and mAb combinations to mice with subcutaneous TC1 tumors; cured mice/mice per group is shown within parentheses. Control mice received equivalent dose of irrelevant IgG mAb (Rat IgG2a). B, Cisplatin plus the 3 mAb combination produces 60% tumor-free survival of mice with TC1 tumors on both sides of the back. The right side tumors were injected intratumorally with the mAbs which were given weekly 3 times; on the first day of treatment cisplatin was injected intraperitoneally. mAbs indicates monoclonal antibodies.